Talphera Discusses Early Termination of Niyad Clinical Trial and Announces Q3 2026 Results
TLPH Talphera Inc
$1.03 -1.43%
View chart & analysis → - 1Talphera, Inc. reported its Q3 2026 regulatory strategy and the progress of the Niyad clinical trial.
- 2CEO Vincent Angotti submitted a document to the US FDA requesting early termination of the clinical trial, citing an enrollment rate exceeding 75% of Talphera's planned target and 80% statistical power of the study.
- 3CFO Rafi Asadorian announced Talphera's cash balance of $14.2 million as of September 30, 2026.
So what's the key point?
Talphera has requested the US FDA to end its clinical trial early because the trial is progressing well. The company holds $14.2 million in cash.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.